We use a few cookies

Essential cookies keep the library working. With your permission, we'd also like to use analytics to see what's useful and improve the experience. Read our Privacy Policy or Cookie Policy.

Skip to main content
Home/e-Resources/Medical Sciences/A Review on Current Repurposing Drugs for the Treatment of COVID-19: Reality and Challenges
PeriodicalsMedical Sciences

A Review on Current Repurposing Drugs for the Treatment of COVID-19: Reality and Challenges

Checking your access to this record.

Abstract & Overview

The coronavirus disease 2019 (COVID-19) caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a global pandemic with a high growth rate of confirmed cases. Therefore, therapeutic options are desperately urgent to fight with this damning virus. As it may take years to develop a specific therapy of COVID-19, it is urgent to emphasize the repurposing of drugs used for other conditions. This study reviewed the most common drugs for COVID-19 based on available online literature representing the latest in vitro clinical trial database, rational of use, adverse effects, potential toxicities, and US National Institute of Health (NIH) recommendation to use for COVID-19. Based on the preliminary data from clinical trials and considering the NIH and FDA recommendation, remdesivir and convalescent blood products are the most promising potential for COVID-19 treatment. The use of chloroquine, hydroxychloroquine, favipiravir, ivermectin, and colchicine might also be effective. However, furthermore, in vivo investigations are needed in detail individually and in combination for possible benefits in humans. Besides, tocilizumab might be deemed as adjunctive therapy for patients with cytokine release syndrome. However, lopinavir-ritonavir, anakinra, and sarilumab had not proven their clinical efficacy. Eventually, sarilumab has been withdrawn from sponsored clinical trials based on the preliminary data. Baricitinib and ruxolitinib have the additive immunosuppressive effect. Consequently, all of these drugs are being evaluated with further studies. In addition, drug-drug interaction and safety concerns must be taken into account before the administration of the recommended drugs.

Cite this record

Md. Shafiul Hossen, Md Abdul Barek, Nusrat Jahan, Mohammad Safiqul Islam (2020). A Review on Current Repurposing Drugs for the Treatment of COVID-19: Reality and Challenges. SN Comprehensive Clinical Medicine, 2(10), 1777–1789. https://doi.org/10.1007/s42399-020-00485-9

Copy in another style

Hossen, M. S., Barek, M. A., Jahan, N., & Islam, M. S. (2020). A Review on Current Repurposing Drugs for the Treatment of COVID-19: Reality and Challenges. SN Comprehensive Clinical Medicine, 2(10), 1777–1789. https://doi.org/10.1007/s42399-020-00485-9
Author names are used as deposited, so check their order before you submit.

Metadata is harvested from open-access indexes and can be incomplete. Check a citation against the published version before relying on it — see our open access & attribution policy.